ArticleThe journal of headache and pain2017
OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study.
Article in The journal of headache and pain, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data.Cephalalgia : an international journal of headache · 2022Pooled it
- High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis.Journal of translational medicine · 2021Pooled it
- Migraine and sleep disorders: a systematic review.The journal of headache and pain · 2020Pooled it
- OnabotulinumtoxinA Improves Sleep Quality in Patients with Chronic Migraine: A Prospective Real-World Study.Toxins · 2026Observational
- Insomnia severity in migraine: The role of headache frequency, aura status, and comorbidities-A cross-sectional study.Headache · 2026Article
- Sleep quality and associated factors in adults living in the southern Brazil: A population-based study.Sleep medicine: X · 2024Article
- Beyond Pain: The Effects of OnabotulinumtoxinA Therapy on Sensitization and Interictal Symptoms in Chronic Migraine.Toxins · 2024Review
- Exploring the symptoms and sleep disorders associated with migraines in women of Syria: A cross-sectional observational study.Health science reports · 2024Article
- The effectiveness and predictors influencing the outcome of onabotulinumtoxinA treatment in chronic migraine: understanding from diverse patient profiles in a single session.Frontiers in neurology · 2024Article
- Effectiveness of galcanezumab on sleep quality, migraine outcome, and multidimensional patient-reported outcome measures: a real-world experience in Turkish patients with episodic and chronic migraine.Frontiers in neurology · 2024Article
- Article
- Review
- Current Perspectives on the Impact of Chronic Migraine on Sleep Quality: A Literature Review.Nature and science of sleep · 2022Review
- OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy.Journal of clinical medicine · 2021Review
- Migraine and Sleep-An Unexplained Association?International journal of molecular sciences · 2021Review
- The Use of Botulinum Toxin for Treatment of Depression.Handbook of experimental pharmacology · 2021Article
- Observational
- Observational
- Response to BotulinumtoxinA in a migraine cohort with multiple comorbidities and widespread pain.Regional anesthesia and pain medicine · 2019Article
- Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation.The journal of headache and pain · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOnabotulinumtoxinA (OnabotA) is considered effective in in patients with chronic migraine (CM) who failed on traditional therapies. This study was designed to evaluate the effect of OnabotA injection series on migraine outcome, negative emotional states and sleep quality in patients with CM.
methodsA total of 190 patients with CM (mean (SD) age: 39.3 (10.2) years; 87.9% were female) were included. Data on Pittsburgh sleep quality index (PSQI), headache frequency and severity, number of analgesics used, Migraine Disability Assessment Scale. (MIDAS) scores and Depression, Anxiety and Stress Scale (DASS-21) were evaluated at baseline (visit 1) and 4 consecutive follow up visits, each conducted after OnabotA injection series; at week 12 (visit 2), week 24 (visit 3), week 36 (visit 4) and week 48 (visit 5) to evaluate change from baseline to follow up.
resultsFrom baseline to visit 5, significant decrease was noted in least square (LS) mean headache frequency (from 19.5 to 8.4, p = 0.002), headache severity (from 8.1 to 6.1, p = 0.017), number of analgesics (from 26.9 to 10.4, p = 0.023) and MIDAS scores (from 67.3 to 18.5, p < 0.001). No significant change from baseline was noted in global PSOI and DASS-21 scores throughout the study.
conclusionsOur findings revealed that OnabotA therapy was associated with significant improvement in migraine outcome leading to decrease in headache frequency and severity, number of analgesics used and MIDAS scores. While no significant change was noted in overall sleep quality and prevalence of negative emotional states, patients without negative emotional states at baseline showed improved sleep quality throughout the study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.